{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:24:47Z","timestamp":1794558287167,"version":"4.9.1"},"publisher-location":"New York, NY","reference-count":44,"publisher":"Springer New York","isbn-type":[{"value":"9781493974924","type":"print"},{"value":"9781493974931","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-1-4939-7493-1_15","type":"book-chapter","created":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T10:44:22Z","timestamp":1516185862000},"page":"297-331","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Robust Optimization Approach to Cancer Treatment under Toxicity Uncertainty"],"prefix":"10.1007","author":[{"given":"Junfeng","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidreza","family":"Badri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Leder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,18]]},"reference":[{"key":"15_CR1","volume":"67","author":"Z Shi","year":"2007","unstructured":"Shi Z, Peng XX, Kim IW et al (2007) Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 67:1101220","journal-title":"Cancer Res"},{"key":"15_CR2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2954","volume":"71","author":"KH Paraiso","year":"2011","unstructured":"Paraiso KH, Xiang Y, Rebecca VW et al (2011) PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71:27502760","journal-title":"Cancer Res"},{"key":"15_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jtbi.2014.02.025","volume":"355","author":"J Foo","year":"2014","unstructured":"Foo J, Michor F (2014) Evolution of acquired resistance to anti-cancer therapy. J Theor Biol 355:10","journal-title":"J Theor Biol"},{"issue":"11","key":"15_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027682","volume":"6","author":"K Leder","year":"2011","unstructured":"Leder K, Foo J, Skaggs B et al (2011) Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. PLoS One 6(11):e27682. https:\/\/doi.org\/10.1371\/journal.pone.0027682","journal-title":"PLoS One"},{"issue":"4","key":"15_CR5","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1214\/12-AAP876","volume":"23","author":"J Foo","year":"2013","unstructured":"Foo J, Leder K (2013) Dynamics of cancer recurrence. Annals Appl Probab 23(4):1437\u20131468","journal-title":"Annals Appl Probab"},{"issue":"1","key":"15_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2003.06.001","volume":"216","author":"KR Swanson","year":"2003","unstructured":"Swanson KR, Bridge C, Murray JD et al (2003) Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion. J Neurol Sci 216(1):1\u201310","journal-title":"J Neurol Sci"},{"issue":"1","key":"15_CR7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1088\/0031-9155\/61\/1\/338","volume":"61","author":"H Badri","year":"2015","unstructured":"Badri H, Watanabe Y, Leder K (2015) Optimal radiotherapy dose schedules under parametric uncertainty. Phys Med Biol 61(1):338","journal-title":"Phys Med Biol"},{"issue":"8","key":"15_CR8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8):735\u2013742","journal-title":"Lancet Oncol"},{"key":"15_CR9","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031\u20131037","journal-title":"N Engl J Med"},{"key":"15_CR10","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A et al (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645\u2013652","journal-title":"N Engl J Med"},{"issue":"3","key":"15_CR11","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes JE, Jones D, O\u2019Brien S et al (2010) Results of dasatinib in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 28(3):398\u2013404","journal-title":"J Clin Oncol"},{"key":"15_CR12","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2010.110","volume":"24","author":"FJ Giles","year":"2010","unstructured":"Giles FJ, Abruzzese E, Rosti G et al (2010) Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia 24:1299\u20131301","journal-title":"Leukemia"},{"key":"15_CR13","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O\u2019Hare","year":"2007","unstructured":"O\u2019Hare T, Eide CA, Deininger MWN (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110:2242\u20132249","journal-title":"Blood"},{"key":"15_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1005129","volume":"12","author":"Q He","year":"2016","unstructured":"He Q, Zhu JF, Dingli D et al (2016) Optimized treatment schedules for chronic myeloid leukemia. PLoS Comput Biol 12:e1005129","journal-title":"PLoS Comput Biol"},{"issue":"12","key":"15_CR15","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1016\/j.compchemeng.2009.06.005","volume":"33","author":"JM Harrold","year":"2009","unstructured":"Harrold JM, Parker RS (2009) Clinically relevant cancer chemotherapy dose scheduling via mixedinteger optimization. Comput Chem Eng 33(12):2042\u20132054","journal-title":"Comput Chem Eng"},{"issue":"1","key":"15_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/0025-5564(90)90047-3","volume":"100","author":"JM Murray","year":"1990","unstructured":"Murray JM (1990) Some optimal control problems in cancer chemotherapy with a toxicity limit. Math Biosci 100(1):49\u201367","journal-title":"Math Biosci"},{"key":"15_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/0025-5564(90)90129-M","volume":"98","author":"JM Murray","year":"1990","unstructured":"Murray JM (1990) Optimal control for a cancer chemotherapy problem with general growth and loss functions. Math Biosci 98:273\u2013287","journal-title":"Math Biosci"},{"issue":"2","key":"15_CR18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1109\/TBME.2013.2280189","volume":"61","author":"MM Hadjiandreou","year":"2014","unstructured":"Hadjiandreou MM, Mitsis GG (2014) Mathematical modeling of tumor growth, drug-resistance, toxicity, and optimal therapy design. IEEE Trans Biomed Eng 61(2):415\u2013425","journal-title":"IEEE Trans Biomed Eng"},{"issue":"3","key":"15_CR19","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/bjc.1964.55","volume":"18","author":"AK Laird","year":"1964","unstructured":"Laird AK (1964) Dynamics of tumour growth. Br J Cancer 18(3):490\u2013502","journal-title":"Br J Cancer"},{"key":"15_CR20","doi-asserted-by":"publisher","first-page":"11131123","DOI":"10.1016\/0005-1098(92)90054-J","volume":"28","author":"RB Martin","year":"1992","unstructured":"Martin RB (1992) Optimal control drug scheduling of cancer chemotherapy. Automatica 28:11131123","journal-title":"Automatica"},{"key":"15_CR21","unstructured":"Floares A Neural networks control of drug dosage regimens in cancer chemotherapy. SAIA, Cluj-Napoca, Transilvania"},{"key":"15_CR22","unstructured":"Weisstein, Eric W. Heaviside step function. MathWorld"},{"key":"15_CR23","doi-asserted-by":"crossref","unstructured":"Afenya EK (2001) Recovery of normal hemopoiesis in disseminated cancer therapy-a model. Math Biosci 172","DOI":"10.1016\/S0025-5564(01)00061-X"},{"key":"15_CR24","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/nature03669","volume":"435","author":"F Michor","year":"2005","unstructured":"Michor F, Hughes TP, Iwasa Y et al (2005) Dynamics of chronic myeloid leukaemia. Nature 435:1267\u20131270","journal-title":"Nature"},{"key":"15_CR25","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00747","volume":"2","author":"I Bozic","year":"2013","unstructured":"Bozic I, Reiter JG, Allen B et al (2013) Evolutionary dynamics of cancer in response to targeted combination therapy. Elife 2:e00747","journal-title":"Elife"},{"key":"15_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.mbs.2007.05.003","volume":"210","author":"S Nanda","year":"2007","unstructured":"Nanda S, Moore H, Lenhart S (2007) Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. Math Biosci 210:143","journal-title":"Math Biosci"},{"issue":"9","key":"15_CR27","doi-asserted-by":"publisher","first-page":"984","DOI":"10.6004\/jnccn.2009.0065","volume":"7","author":"S O\u2019Brien","year":"2009","unstructured":"O\u2019Brien S, Berman E, Borghaei H et al (2009) NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw 7(9):984\u20131023","journal-title":"J Natl Compr Canc Netw"},{"key":"15_CR28","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M et al (1984) Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood 63:789\u2013799","journal-title":"Blood"},{"key":"15_CR29","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R et al (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90:850\u2013858","journal-title":"J Natl Cancer Inst"},{"key":"15_CR30","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1038\/sj.onc.1205317","volume":"21","author":"B Scheijen","year":"2002","unstructured":"Scheijen B, Griffin JD (2002) Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene 21:3314","journal-title":"Oncogene"},{"issue":"8","key":"15_CR31","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","volume":"21","author":"MW Deininger","year":"2003","unstructured":"Deininger MW, O\u2019Brien S, Ford JM et al (2003) Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 21(8):1637\u20131647","journal-title":"J Clin Oncol"},{"key":"15_CR32","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3109\/07357907.2015.1065499","volume":"33","author":"BBP Katia","year":"2015","unstructured":"Katia BBP, Israel B, Carla B et al (2015) BCR-ABL mutations in Chronic Myeloid Leukemia treated with tyrosine kinase inhibitors and impact on survival. Cancer Invest 33:451\u2013458","journal-title":"Cancer Invest"},{"issue":"20","key":"15_CR33","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","volume":"114","author":"JG Ravin","year":"2009","unstructured":"Ravin JG, Hagop K, Susan O et al (2009) The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 114(20):4361","journal-title":"Blood"},{"key":"15_CR34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1756-8722-3-47","volume":"3","author":"G Wei","year":"2010","unstructured":"Wei G, Rafiyath S, Liu D (2010) First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol 3:47","journal-title":"J Hematol Oncol"},{"issue":"1","key":"15_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.suponc.2011.08.001","volume":"10","author":"M Cornelison","year":"2012","unstructured":"Cornelison M, Jabbour EJ, Welch MA (2012) Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner. J Support Oncol 10(1):14\u201324","journal-title":"J Support Oncol"},{"issue":"2","key":"15_CR36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5581\/1516-8484.20110034","volume":"33","author":"M Conchon","year":"2011","unstructured":"Conchon M, Freitas CM, Rego MA et al (2011) Dasatinib - clinical trials and management of adverse events in imatinib resistant\/intolerant chronic myeloid leukemia. Rev Bras Hematol Hemoter 33(2):131\u2013139","journal-title":"Rev Bras Hematol Hemoter"},{"key":"15_CR37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/asheducation.V2012.1.115.3798209","volume":"1","author":"D Marin","year":"2012","unstructured":"Marin D (2012) Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia. Hematology Am Soc Hematol Educ Program 1:115\u2013121","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"15_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1000503","volume":"5","author":"J Foo","year":"2009","unstructured":"Foo J, Drummond MW, Clarkson B et al (2009) Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Comput Biol 5(9):e1000503","journal-title":"PLoS Comput Biol"},{"key":"15_CR39","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/leu.2011.187","volume":"26","author":"FX Gruber","year":"2012","unstructured":"Gruber FX, Ernst T, Porkka K et al (2012) Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients. Leukemia 26:172\u2013177","journal-title":"Leukemia"},{"issue":"3","key":"15_CR40","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes JE, Jones D, O\u2019Brien S et al (2010) Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 28(3):392\u2013397","journal-title":"J Clin Oncol"},{"issue":"19","key":"15_CR41","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","volume":"120","author":"JP Radich","year":"2012","unstructured":"Radich JP, Kopecky KJ, Appelbaum FR et al (2012) A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 120(19):3898\u20133905","journal-title":"Blood"},{"key":"15_CR42","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood.V112.11.3236.3236","volume":"112","author":"M Deininger","year":"2008","unstructured":"Deininger M, Mauro M, Matloub Y et al (2008) Prevalence of T315I, dasatinib-specific resistant mutations (F317L, V299L, and T315A), and nilotinib-specific resistant mutations (P-loop and F359) at the time of imatinib resistance in chronic-phase chronic myeloid leukemia (CP-CML). Blood 112:3236","journal-title":"Blood"},{"key":"15_CR43","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/nature03095","volume":"432","author":"C Sawyers","year":"2004","unstructured":"Sawyers C (2004) Targeted cancer therapy. Nature 432:294\u2013297","journal-title":"Nature"},{"key":"15_CR44","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","volume":"11","author":"J Cortes","year":"2005","unstructured":"Cortes J, Talpaz M, O\u2019Brien S et al (2005) Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 11:3425","journal-title":"Clin Cancer Res"}],"container-title":["Methods in Molecular Biology","Cancer Systems Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-7493-1_15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T15:17:47Z","timestamp":1603639067000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-7493-1_15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9781493974924","9781493974931"],"references-count":44,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-7493-1_15","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-4939-7493-1","asserted-by":"object"}]},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"18 January 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}